CR20150228A - Inhibidores de la tirosina-quinasa de bruton - Google Patents

Inhibidores de la tirosina-quinasa de bruton

Info

Publication number
CR20150228A
CR20150228A CR20150228A CR20150228A CR20150228A CR 20150228 A CR20150228 A CR 20150228A CR 20150228 A CR20150228 A CR 20150228A CR 20150228 A CR20150228 A CR 20150228A CR 20150228 A CR20150228 A CR 20150228A
Authority
CR
Costa Rica
Prior art keywords
bruton
tirosina
quinasa
inhibitors
compounds
Prior art date
Application number
CR20150228A
Other languages
English (en)
Inventor
John Robert Springer
Balekudru Devadas
Danny James Garland
Margaret Lanahan Grapperhaus
Seungil Han
Susan Landis Hockerman
Robert Owen Hughes
Eddine Saiah
Mark Edward Schnute
Shaun Raj Selness
Daniel Patrick Walker
Zhao-Kui Wan
Li Xing
Christoph Wolfgang Zapf
Michelle Ann Schmidt
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49596360&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20150228(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of CR20150228A publication Critical patent/CR20150228A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen en la presente compuestos que forman enlaces covalentes con tirosina quinasa de Bruton (BTK). Se describen los 5 métodos para la preparación de los compuestos. Se describen también composiciones farmacéuticas que incluyen los compuestos.
CR20150228A 2012-11-02 2015-04-30 Inhibidores de la tirosina-quinasa de bruton CR20150228A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261721920P 2012-11-02 2012-11-02
US201361772028P 2013-03-04 2013-03-04
PCT/IB2013/059846 WO2014068527A1 (en) 2012-11-02 2013-11-01 Bruton's tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
CR20150228A true CR20150228A (es) 2015-09-14

Family

ID=49596360

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20150228A CR20150228A (es) 2012-11-02 2015-04-30 Inhibidores de la tirosina-quinasa de bruton

Country Status (27)

Country Link
US (4) US20150291554A1 (es)
EP (1) EP2914586B1 (es)
JP (1) JP6178861B2 (es)
KR (1) KR101668574B1 (es)
CN (1) CN105008344B (es)
AP (1) AP2015008381A0 (es)
AU (1) AU2013340345B2 (es)
BR (1) BR112015009624A2 (es)
CA (1) CA2888960C (es)
CL (1) CL2015001168A1 (es)
CO (1) CO7350624A2 (es)
CR (1) CR20150228A (es)
DO (1) DOP2015000100A (es)
EA (1) EA201500393A1 (es)
ES (1) ES2625944T3 (es)
GE (1) GEP201606597B (es)
HK (1) HK1211293A1 (es)
IL (1) IL238571A0 (es)
MD (1) MD20150035A2 (es)
MX (1) MX2015005422A (es)
NI (1) NI201500059A (es)
PE (1) PE20151070A1 (es)
PH (1) PH12015500940A1 (es)
SG (1) SG11201502893WA (es)
TN (1) TN2015000168A1 (es)
TW (1) TWI518080B (es)
WO (1) WO2014068527A1 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2882741B1 (en) 2012-08-10 2018-10-24 Boehringer Ingelheim International GmbH Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
ES2731833T3 (es) 2012-09-10 2019-11-19 Principia Biopharma Inc Compuestos pirazolopirimidínicos comos inhibidores de cinasas
CN103848810A (zh) * 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
EP2970163B1 (en) 2013-03-14 2018-02-28 Boehringer Ingelheim International GmbH 5-thiazolecarboxamide dervatives and their use as btk inhibitors
WO2014152114A1 (en) 2013-03-15 2014-09-25 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as btk inhibitors
MY194905A (en) * 2013-03-15 2022-12-22 Janssen Pharmaceutica Nv Processes and Intermediates for Preparing a Medicament
US9156847B2 (en) * 2013-03-15 2015-10-13 Janssen Pharmaceutica Nv Processes and intermediates for preparing a medicament
KR102503010B1 (ko) * 2013-08-19 2023-02-24 타리스 바이오메디컬 엘엘씨 다중 유닛 약물 전달 장치 및 방법
RS60934B1 (sr) * 2013-09-30 2020-11-30 Guangzhou Innocare Pharma Tech Co Ltd Supstituisani nikotinimidni inhibitori btk i njihova priprema i upotreba u lečenju karcinoma, inflamatorne i autoimune bolesti
EP3099674B1 (en) * 2014-01-29 2018-10-24 Boehringer Ingelheim International Gmbh Pyrazole compounds as btk inhibitors
EA033900B1 (ru) 2014-02-21 2019-12-06 Принсипиа Биофарма Инк. СОЛЕВЫЕ И АМОРФНЫЕ ФОРМЫ 2-[(3R)-3-[4-АМИНО-3-(2-ФТОР-4-ФЕНОКСИФЕНИЛ)ПИРАЗОЛО[3,4-d]ПИРИМИДИН-1-ИЛ]ПИПЕРИДИН-1-КАРБОНИЛ]-4-МЕТИЛ-4-[4-(ОКСЕТАН-3-ИЛ)ПИПЕРАЗИН-1-ИЛ]ПЕНТ-2-ЕННИТРИЛА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ПУЗЫРЧАТКИ ОБЫКНОВЕННОЙ И ПУЗЫРЧАТКИ ЛИСТОВИДНОЙ С ИХ ПРИМЕНЕНИЕМ
WO2015185998A2 (en) * 2014-04-11 2015-12-10 Acerta Pharma B.V. Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase
CN105085474B (zh) 2014-05-07 2018-05-18 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
GB201410430D0 (en) 2014-06-11 2014-07-23 Redx Pharma Ltd Compounds
TW201607930A (zh) * 2014-07-18 2016-03-01 百濟神州有限公司 作為ｔ７９０ｍ／ｗｔ－ｅｇｆｒ的選擇性和不可逆的激酶抑制劑的５－氨基－４－氨甲醯基－吡唑化合物及其用途
WO2016019237A2 (en) * 2014-07-31 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
CN105884747B (zh) * 2014-08-28 2021-01-05 首药控股(北京)有限公司 一种制备布鲁顿酪氨酸激酶(btk)激酶抑制剂的制备方法
ES2843323T3 (es) 2014-12-18 2021-07-16 Principia Biopharma Inc Tratamiento de pénfigo
WO2016192074A1 (en) * 2015-06-04 2016-12-08 Merck Sharp & Dohme Corp. Btk inhibitors
TW201718572A (zh) 2015-06-24 2017-06-01 普林斯匹亞生物製藥公司 酪胺酸激酶抑制劑
KR20180109842A (ko) 2015-09-16 2018-10-08 록쏘 온콜로지, 인코포레이티드 화합물
MX2018005463A (es) * 2015-11-17 2018-08-01 Merck Patent Gmbh Metodos para tratar esclerosis multiple usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton.
AU2016370743B2 (en) 2015-12-16 2020-11-26 Boehringer Ingelheim International Gmbh Bipyrazolyl derivatives useful for the treatment of autoimmune diseases
EA035132B1 (ru) * 2015-12-16 2020-04-30 Локсо Онколоджи, Инк. Соединения, которые можно применять в качестве ингибиторов киназы
WO2017123695A1 (en) 2016-01-13 2017-07-20 Boehringer Ingelheim International Gmbh Isoquinolones as btk inhibitors
CN107021963A (zh) 2016-01-29 2017-08-08 北京诺诚健华医药科技有限公司 吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用
MA43753A (fr) 2016-03-24 2018-11-28 Mission Therapeutics Ltd Dérivés 1-cyano-pyrrolidine comme inhibiteurs de dbu
EP3459940B8 (en) * 2016-05-16 2022-08-24 Evopoint Biosciences Co., Ltd. 5-aminopyrazole carboxamide derivative as btk inhibitor and preparation method and pharmaceutical composition thereof
MX2018016056A (es) 2016-06-29 2019-07-04 Principia Biopharma Inc Formulaciones de liberacion modificada de 2-[3-[4-amino-3-(2-fluor o-4-fenoxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidina-1-carbo nil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enenitrilo.
GB201616511D0 (en) * 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
TWI771327B (zh) * 2016-10-05 2022-07-21 英商使命醫療公司 新穎化合物
WO2018102785A2 (en) 2016-12-03 2018-06-07 Juno Therapeutics, Inc. Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors
EA202090871A1 (ru) 2017-10-06 2020-07-03 Форма Терапьютикс, Инк. Ингибирование убиквитин-специфической пептидазы 30
CN111225669B (zh) * 2017-11-10 2020-12-29 苏州信诺维医药科技有限公司 作为btk抑制剂的5-氨基吡唑甲酰胺化合物的晶型i
WO2019091441A1 (zh) * 2017-11-10 2019-05-16 苏州信诺维医药科技有限公司 作为btk抑制剂的5-氨基吡唑甲酰胺化合物及其制备方法
WO2019091438A1 (zh) * 2017-11-10 2019-05-16 苏州信诺维医药科技有限公司 作为btk抑制剂的5-氨基吡唑甲酰胺化合物的无定型固体分散体
JP7449242B2 (ja) 2018-05-17 2024-03-13 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的ペプチダーゼ３０（ｕｓｐ３０）阻害剤として有用な縮合二環化合物
CN108530436B (zh) * 2018-05-17 2020-12-29 黄传满 一种吡唑类化合物及其制备方法和应用
DK3860989T3 (da) 2018-10-05 2023-05-01 Forma Therapeutics Inc Kondenserede pyrroliner der fungerer som inhibitorer af ubiquitin-specifik protease 30 (usp30)
MX2024010859A (es) * 2019-03-14 2024-09-11 Calico Life Sciences Llc Inhibidores de la proteina tirosina fosfatasa y metodos para usarlos.
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2020234379A1 (en) * 2019-05-21 2020-11-26 Janssen Pharmaceutica Nv Processes and intermediates for preparing a btk inhibitor
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
TWI809489B (zh) * 2020-09-10 2023-07-21 美商絡速藥業公司 用於製備(s)-5-胺基-3-(4-((5-氟-2-甲氧基苯甲醯胺基)甲基)苯基)-1-(1,1,1-三氟丙烷-2-基)-1h-吡唑-4-甲醯胺之方法及中間體
WO2022140246A1 (en) 2020-12-21 2022-06-30 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
WO2023284765A1 (zh) * 2021-07-16 2023-01-19 深圳市塔吉瑞生物医药有限公司 取代的吡唑类化合物及包含该化合物的组合物及其用途
WO2023150663A1 (en) * 2022-02-04 2023-08-10 Retune Pharma Inc. Certain chemical entities, compositions, and methods
WO2024153226A1 (zh) * 2023-01-19 2024-07-25 北京普祺医药科技股份有限公司 一种吡唑并环类化合物、药物组合物及其用途
WO2024153237A1 (zh) * 2023-01-19 2024-07-25 北京普祺医药科技股份有限公司 一种igf-1r酪氨酸激酶抑制剂、药物组合物及其用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US6326469B1 (en) 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
GB9608435D0 (en) * 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
WO2003072541A2 (en) * 2001-09-27 2003-09-04 Smithkline Beecham Corporation Chemical compounds
WO2007117692A2 (en) 2006-04-11 2007-10-18 Vertex Pharmaceuticals Incorporated Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases
PT2526771T (pt) 2006-09-22 2017-02-27 Pharmacyclics Llc Inibidores de tirosina-cinase de bruton
FR2908409B1 (fr) 2006-11-10 2009-01-09 Sanofi Aventis Sa Pyrazoles substituees,compositions les contenant,procede de fabrication et utilisation
US7897619B2 (en) * 2007-07-17 2011-03-01 Amgen Inc. Heterocyclic modulators of PKB
JP5369183B2 (ja) * 2008-07-16 2013-12-18 ファーマサイクリックス，インク． 固形腫瘍の治療用のブルートンのチロシンキナーゼの阻害剤
CN102105459B (zh) 2008-07-24 2014-09-10 内尔维阿诺医学科学有限公司 作为蛋白激酶抑制剂的3,4-二芳基吡唑类
DK2473049T3 (en) * 2009-09-04 2019-04-01 Biogen Ma Inc INHIBITORS OF BRUTON'S TYROSINKINASE
EP2582668B1 (en) * 2010-06-16 2016-01-13 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
EP2882741B1 (en) * 2012-08-10 2018-10-24 Boehringer Ingelheim International GmbH Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
CN103848810A (zh) * 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
FR3002733B1 (fr) 2013-03-04 2015-08-14 Servier Lab Nouveau sel de l'abexinostat, forme cristalline associee,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN106132507A (zh) 2014-04-09 2016-11-16 唐纳森公司 自承式折叠的片材材料以及过滤元件
CN105085474B (zh) * 2014-05-07 2018-05-18 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂

Also Published As

Publication number Publication date
US20190202798A1 (en) 2019-07-04
WO2014068527A1 (en) 2014-05-08
BR112015009624A2 (pt) 2017-11-14
US10266513B2 (en) 2019-04-23
EP2914586B1 (en) 2017-04-05
US20170283393A1 (en) 2017-10-05
PH12015500940A1 (en) 2015-06-29
GEP201606597B (en) 2017-01-10
US10815213B2 (en) 2020-10-27
TN2015000168A1 (fr) 2016-10-03
MD20150035A2 (ro) 2015-10-31
EA201500393A1 (ru) 2016-05-31
CL2015001168A1 (es) 2015-07-10
JP2015535277A (ja) 2015-12-10
DOP2015000100A (es) 2015-12-31
MX2015005422A (es) 2015-08-05
ES2625944T3 (es) 2017-07-21
US20210002251A1 (en) 2021-01-07
KR20150075114A (ko) 2015-07-02
US20150291554A1 (en) 2015-10-15
PE20151070A1 (es) 2015-08-01
AU2013340345A1 (en) 2015-04-30
IL238571A0 (en) 2015-06-30
AP2015008381A0 (en) 2015-04-30
CA2888960C (en) 2017-08-15
EP2914586A1 (en) 2015-09-09
AU2013340345B2 (en) 2016-10-27
JP6178861B2 (ja) 2017-08-09
TW201431851A (zh) 2014-08-16
CN105008344A (zh) 2015-10-28
HK1211293A1 (en) 2016-05-20
SG11201502893WA (en) 2015-05-28
NI201500059A (es) 2015-06-05
CO7350624A2 (es) 2015-08-10
CN105008344B (zh) 2017-07-25
KR101668574B1 (ko) 2016-10-24
CA2888960A1 (en) 2014-05-08
TWI518080B (zh) 2016-01-21

Similar Documents

Publication Publication Date Title
CR20150228A (es) Inhibidores de la tirosina-quinasa de bruton
CR20150263A (es) Compuestos de pirrolopirimidina como inhibidores de quinasas
DOP2016000071A (es) Inhibidores de tirosina cinasa de bruton
NI201500140A (es) Compuestos y composiciones terapéuticos
CR20150524A (es) Compuestos de heteroarilo y sus usos
CU20170172A7 (es) 4,6-diaminoquinolin-3-carbonitrilos sustituidos útiles como agentes analgésicos, antipiréticos o antiinflamatorios y antineoplásicos
CR20160141A (es) Formulaciones de anticuerpos anti-pdl1
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
GT201400297A (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen
ECSP15043696A (es) Compuestos de heteroarilo y sus usos
DOP2015000206A (es) Derivados de pirrolo[2,3-d]pirimidina como inhibidores de quinasas janus (jak)
GT201400142A (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY35485A (es) Compuestos heterocíclicos y usos de los mismos
GT201400178A (es) Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de la pi3ks
CO7160104A2 (es) Inhibidores de virus de hepatitis c
UY34779A (es) Anticuerpos anti-il-23 y composiciones farmacéuticas que los contienen
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
DOP2018000062A (es) Piridinona dicaboxamidas para uso como inhibidores de bromodominio
GT201500094A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
BR112018011526A2 (pt) compostos policíclicos como inibidores da tirosina quinase de bruton
NI201500096A (es) Compuesto químicos
BR112018011525A2 (pt) inibidores da tirosina quinase de bruton e métodos de seu uso
CO7151478A2 (es) Formulaciones estabilizadas que contienen anticuerpos anti-dll4
GT201400007A (es) Sales de éteres aza bicíclicos de di-arilo y métodos para preparar los mismos o sus precursores